Compare Stocks → Biden’s Tax Plan Could Destroy Your Retirement Savings! (From GoldenCrest Metals) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDigital Media StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare ShareLink copied to clipboard. NASDAQ:CRGXNASDAQ:HUMANYSE:PRMENASDAQ:RGNX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRGXCARGO Therapeutics$16.72-2.7%$19.48$13.14▼$33.92$658.43MN/A180,498 shs201,373 shsHUMAHumacyte$7.05-2.1%$5.46$1.96▼$9.97$839.51M1.622.83 million shs1.17 million shsPRMEPrime Medicine$7.11-10.0%$6.12$4.11▼$15.75$853.41M2.35945,365 shs668,196 shsRGNXREGENXBIO$12.41-5.1%$15.75$11.83▼$28.80$611.32M1.34414,966 shs531,378 shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRGXCARGO Therapeutics-2.68%-6.90%-20.34%-46.55%+1,671,999,900.00%HUMAHumacyte-2.08%-3.03%+8.96%+117.59%+104.64%PRMEPrime Medicine-10.00%+8.22%+5.18%-0.70%-52.06%RGNXREGENXBIO-5.12%-11.86%-23.54%-44.07%-36.97%Biden’s Tax Plan Could Destroy Your Retirement Savings! (Ad)Leading economists are issuing stark warnings: The anticipated capital gains tax increase under President Biden could drastically undermine your retirement plans by 2025.Learn More TodayMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRGXCARGO Therapeutics2.0821 of 5 stars3.52.00.00.03.13.30.0HUMAHumacyte1.5965 of 5 stars2.42.00.00.02.94.20.6PRMEPrime Medicine3.3765 of 5 stars4.40.00.00.03.13.30.6RGNXREGENXBIO3.89 of 5 stars3.41.00.04.62.63.30.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRGXCARGO Therapeutics3.00Buy$29.0073.44% UpsideHUMAHumacyte2.75Moderate Buy$8.0013.48% UpsidePRMEPrime Medicine2.83Moderate Buy$15.09112.25% UpsideRGNXREGENXBIO2.85Moderate Buy$38.58210.91% UpsideCurrent Analyst RatingsLatest HUMA, CRGX, RGNX, and PRME Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/7/2024RGNXREGENXBIOThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$38.005/24/2024HUMAHumacyteBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.005/20/2024PRMEPrime MedicineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$10.005/16/2024CRGXCARGO TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$34.00 ➝ $32.005/16/2024PRMEPrime MedicineCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$10.005/15/2024RGNXREGENXBIOHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$36.00 ➝ $38.005/13/2024HUMAHumacyteBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.005/13/2024PRMEPrime MedicineJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$16.00 ➝ $15.005/7/2024PRMEPrime MedicineJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.00 ➝ $15.004/23/2024PRMEPrime MedicineWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$12.004/22/2024PRMEPrime MedicineChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$17.00(Data available from 6/15/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRGXCARGO TherapeuticsN/AN/AN/AN/A$9.84 per shareN/AHUMAHumacyte$1.57M534.72N/AN/A$0.13 per share54.23PRMEPrime MedicineN/AN/AN/AN/A$1.37 per shareN/ARGNXREGENXBIO$90.24M6.77N/AN/A$7.09 per share1.75Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRGXCARGO Therapeutics-$98.15MN/A0.00N/AN/AN/AN/AN/A8/13/2024 (Estimated)HUMAHumacyte-$110.78M-$1.00N/AN/AN/AN/A-306.81%-69.64%8/12/2024 (Estimated)PRMEPrime Medicine-$198.13M-$2.17N/AN/AN/AN/A-94.21%-74.52%8/5/2024 (Estimated)RGNXREGENXBIO-$263.49M-$5.88N/AN/AN/A-299.96%-70.72%-41.30%8/7/2024 (Estimated)Latest HUMA, CRGX, RGNX, and PRME EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2024Q1 2024CRGXCARGO Therapeutics-$1.05-$0.87+$0.18-$0.87N/AN/A5/10/2024Q1 2024HUMAHumacyte-$0.23-$0.29-$0.06-$0.29N/AN/A5/10/2024Q1 2024PRMEPrime Medicine-$0.45-$0.44+$0.01-$0.44N/A$0.59 million5/8/2024Q1 2024RGNXREGENXBIO-$1.28-$1.38-$0.10-$1.38$23.52 million$15.60 million 3/22/2024Q4 2023HUMAHumacyte-$0.25-$0.24+$0.01-$0.24$0.10 millionN/A 3/21/2024Q4 2023CRGXCARGO Therapeutics-$1.62-$1.49+$0.13-$1.49N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRGXCARGO TherapeuticsN/AN/AN/AN/AN/AHUMAHumacyteN/AN/AN/AN/AN/APRMEPrime MedicineN/AN/AN/AN/AN/ARGNXREGENXBION/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRGXCARGO TherapeuticsN/A16.7816.78HUMAHumacyte0.618.378.37PRMEPrime MedicineN/A8.918.91RGNXREGENXBION/A3.593.59OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRGXCARGO Therapeutics93.16%HUMAHumacyte44.71%PRMEPrime Medicine70.37%RGNXREGENXBIO88.08%Insider OwnershipCompanyInsider OwnershipCRGXCARGO Therapeutics1.38%HUMAHumacyte23.10%PRMEPrime Medicine24.29%RGNXREGENXBIO13.13%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCRGXCARGO Therapeutics11639.38 million38.83 millionN/AHUMAHumacyte183119.08 million91.58 millionOptionablePRMEPrime Medicine234120.03 million90.88 millionOptionableRGNXREGENXBIO34449.26 million42.79 millionOptionableHUMA, CRGX, RGNX, and PRME HeadlinesRecent News About These CompaniesJune 12 at 7:05 AM | prnewswire.comREGENXBIO Announces Leadership TransitionJune 11, 2024 | americanbankingnews.comREGENXBIO (NASDAQ:RGNX) Lowered to Sell at StockNews.comJune 10, 2024 | seekingalpha.comRegenxbio: Transforming Gene Therapy With Innovative AAV Treatments, Strong BuyJune 10, 2024 | marketbeat.comStockNews.com Lowers REGENXBIO (NASDAQ:RGNX) to SellJune 10, 2024 | marketbeat.comREGENXBIO (NASDAQ:RGNX) Trading Down 5%June 9, 2024 | americanbankingnews.comREGENXBIO (NASDAQ:RGNX) Shares Gap Up to $13.76June 7, 2024 | americanbankingnews.comREGENXBIO (NASDAQ:RGNX) Receives New Coverage from Analysts at The Goldman Sachs GroupJune 5, 2024 | prnewswire.comREGENXBIO to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceMay 30, 2024 | marketbeat.comREGENXBIO (NASDAQ:RGNX) Lifted to "Hold" at StockNews.comMay 26, 2024 | marketbeat.comREGENXBIO Inc. (NASDAQ:RGNX) Given Average Rating of "Moderate Buy" by BrokeragesMay 25, 2024 | finance.yahoo.comIt Looks Like REGENXBIO Inc.'s (NASDAQ:RGNX) CEO May Expect Their Salary To Be Put Under The MicroscopeMay 24, 2024 | bovnews.comDon’t be afraid of Regenxbio Inc (RGNX) Stock despite uncertainty and doubtMay 18, 2024 | insidertrades.comKenneth T. Mills Sells 15,000 Shares of REGENXBIO Inc. (NASDAQ:RGNX) StockMay 17, 2024 | insidertrades.comREGENXBIO Inc. (NASDAQ:RGNX) CEO Sells $237,150.00 in StockMay 17, 2024 | marketbeat.comQ2 2024 Earnings Forecast for REGENXBIO Inc. Issued By HC Wainwright (NASDAQ:RGNX)May 16, 2024 | marketbeat.comInsider Selling: REGENXBIO Inc. (NASDAQ:RGNX) CEO Sells 15,000 Shares of StockMay 15, 2024 | markets.businessinsider.comEvaluating Regenxbio: Insights From 9 Financial AnalystsMay 15, 2024 | marketbeat.comHC Wainwright Increases REGENXBIO (NASDAQ:RGNX) Price Target to $38.00May 11, 2024 | finance.yahoo.comAnalysts Have Lowered Expectations For REGENXBIO Inc. (NASDAQ:RGNX) After Its Latest ResultsMay 10, 2024 | finance.yahoo.comRegenxbio Inc (RGNX) Q1 2024 Earnings: Misses Analyst Revenue and EPS ForecastsMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for RegenXBio Amid Promising Drug Developments and Solid FinancialsNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIntel's Secret Plan for a Double-Digit Stock Rally RevealedBy Gabriel Osorio-Mazilli | June 7, 2024View Intel's Secret Plan for a Double-Digit Stock Rally RevealedStock market today: Wall Street hangs around its records after European stocks slumpBy The Associated Press | June 14, 2024View Stock market today: Wall Street hangs around its records after European stocks slumpTop 3 Stocks Set to Soar with the AI-Driven Metaverse RevolutionBy Thomas Hughes | June 10, 2024View Top 3 Stocks Set to Soar with the AI-Driven Metaverse RevolutionCVS Health Stock Has a Silver Lining Called Value By Jea Yu | May 20, 2024View CVS Health Stock Has a Silver Lining Called Value Is Cigna Group the Nation's Best-Run Health Insurance Company?By Jea Yu | May 28, 2024View Is Cigna Group the Nation's Best-Run Health Insurance Company?Company DescriptionsCARGO TherapeuticsNASDAQ:CRGXCARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.HumacyteNASDAQ:HUMAHumacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.Prime MedicineNYSE:PRMEPrime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.REGENXBIONASDAQ:RGNXREGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.